Matthew Taylor Recent News
Barclays Ups C.R. Bard's Price Target By $11
Barclays Bullish On Intuitive Surgical On Heels Of Earnings Report
Abbott Laboratories Is 'A Premium Asset At A Discount,' Says Barclays
Intuitive Surgical's Da Vinci Prostatectomy Bolus 'Has Legs,' Barclays Says
Barclays Likes Abbott Laboratories, Whether Acquisitions Close Or Not
Barclays Sees Upside In Teleflex, Raises Price Target
Barclays Bullish On NuVasive, Globus Medical, Dislikes LDR Holding
Barclays Upgrades Abbott, Sees 'Selling Overdone'
Barclays Initiates Coverage On Life Science Tools & Diagnostics, Names Thermo Fisher As 'Top Pick'
Headwinds For C.R. Bard, According To Barclays